



Fimvo – Counterforce against falsified medicines



EMVO: Updating Product Master Data (PMD) for All Target Markets

EMVO has identified instances where Product Master Data (PMD) is not being correctly updated to reflect new target markets—such as Greece.

All intended markets for your product(s) must be included in the Product Master Data (PMD) uploaded to the EU Hub. This is essential to ensure that the associated batch data can be correctly transmitted to the relevant national systems.

If you are adding a new market to an existing multi-market pack, please ensure that you create **a new version of the PMD** and include all relevant target markets.

For detailed guidance on completing the Product Master Data and Product Pack Data, please consult the [EMVS Master Data Guide](#).

Should you have any questions, please do not hesitate to contact EMVO's Helpdesk (helpdesk@emvo-medicines.eu) or consult EMVO's Self-Service Portal available on their website [here](#).

Deployment of the NMVS release 16 and downtime in the Finnish NMVS production environment on Wednesday, May 21st, 2025

There is a downtime window in the production environment of the Finnish NMVS due to the deployment of the NMVS release 16 starting at 23:00 EET on Wednesday, May 21st and ending at 05:00 EET on May 22nd at the latest.

As a result, end users may not be able to verify packs in real-time and OBPs may not be able to upload data in FiMVS.

We apologise for any inconvenience caused.



News

Nordic recommendations on the use of status 'Locked' in the EMVS

The functionality to mark a pack as locked can provide added value and security in preventing medicines in quarantine or under investigation entering in or going back into the supply chain.

The functionality is not a legal requirement and the use of it is voluntary.

The Nordic medicines verification organisations have published a Best Practice Guide for using this feature in the system.

[Please find the guide here](#)

Fimvo SGA on 21st March 2025 - Our Board continues the work to fight against falsified medicines

Fimvo held its Statutory General Assembly on 21st March 2025 where the new Board was confirmed.

[Check the new Board here and get to know them!](#)

The founders and Board members of Fimvo are Pharma Industry Finland, Orion Corporation, the Finnish Generic Pharmaceutical Association, Suppliers of Parallel Imported Medicines in Finland, the Association of Finnish Pharmacies and the Association of Pharmaceutical Distributors.

The Growing Threat of Pharmaceutical Crime

Europol's recent report The Threat of Pharmaceutical Crime in the EU and Beyond warns of the increasing prevalence of international pharmaceutical crime. There is a rising number of cases in which falsified medicines have entered the global supply chain. The use of such products can lead to serious health issues. These falsifications are produced for financial gain and often fund organised crime.

[Read more](#)



Contact us!

Regarding contracts and invoices:

info@fimvo.fi

Regarding alerts and medicines verification system:

nmvs@fimvo.fi



Suomen Lääkevarmennus Oy

Itämerentori 2
00180 Helsinki



Suomen Lääkevarmennus Oy:n asiakasrekisteri / FiMVO client register
[Tietosuojaseloste](#) / [Privacy policy](#) | [Peruuta tilauksesi](#) / [Unsubscribe](#)